ESMO Annual Congress

The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.

The addition of avelumab to standard first-line gemcitabine/carboplatin did not improve outcomes in patients with metastatic urothelial carcinoma.

The combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

The addition of the AKT inhibitor ipatasertib to abiraterone acetate and prednisone improved radiographic progression-free survival, with overall survival data still eagerly anticipated.

The antibody-drug conjugate enfortumab vedotin significantly improved overall survival versus chemotherapy in a phase 3 trial.

Investigators also reported that a subgroup of patients with 1 or more target kidney lesions experienced kidney tumor reduction and other benefits from the combination treatment.

Pivotal phase 3 trial launched to confirm promising results in metastatic urothelial carcinoma.

“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.